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Assessing the Health Economic 
Agreement of Different Data Sources. 
 
ABSTRACT 
A simple to use framework for assessing the agreement of cost-effectiveness endpoints generated 
from different sources of data is presented. The aim of this package is to enable the rapid 
assessment of routine data for utilisation in cost-effectiveness analyses. By quantifying the 
comparability of routine data with ‘gold standard’ trial data, decisions on the suitability of routine 
data for cost-effectiveness analysis are informed. The rapid identification of informative routine data 
will increase the opportunity for economic analyses and potentially reduce the cost and burden of 
collecting patient reported data in clinical trials.  
1 INTRODUCTION   
With healthcare budgets under increasing scrutiny, the economic analysis of clinical decision making 
is of growing importance. This extends to the collection of evidence (1, 2). There is increasing 
pressure to gather information and make decisions most cost-effectively. Health economists 
routinely use data generated from clinical trials to assess the cost-effectiveness of interventions, 
however it can take months or years for the patient follow up to be completed. This delay, alongside 
the cost and burden placed on patients to complete lengthy study questionnaires, provides 
opportunities to consider alternative approaches.  
There is increasing interest in the use of routine data to inform clinical decision making, due to its 
potential for identifying cost-effective solutions rapidly and inexpensively (3, 4). However, the utility 
of routine data for this purpose remains uncertain. This issue can be informed by identifying the 
level of agreement between routine data and a ‘gold standard’ such as existing trials data.  Whilst 
questions remain over what is an acceptable level of agreement, this paper introduces a simple to 
use tool which quantifies the agreement between final economic endpoints generated using 
alternative sources of cost effectiveness data.  The routines implemented within this tool are 
suitable for use in a wide variety of decision making contexts. For example, they can be used to 
compare and validate routine data for use in trial-based economic evaluations when alternative 
source of information on costs and effects are available for trial participants.  
Achana et al(5) introduced a methodological framework for the assessment of agreement, utilising 
Lin’s Concordance Correlation Coefficient (CCC)(6), the difference in Incremental Net Benefit (INB) 
estimates, the Probability of Miscoverage (PMC) and the Probability of Cost Effectiveness (PCE). 
Building on this work, generalisable commands are presented allowing these analyses to be 
performed with relative ease. The commands are designed for use when data similar to those 
generated by a typical two arm clinical trial are available. 
Using individual patient data, the commands assist with the calculation of the incremental cost-
effectiveness ratio (ICER) and INB.  Briefly, the ICER is the ratio of incremental costs (i.e. difference in 
mean costs between the treatment and control interventions) to incremental effectiveness (i.e. the 
corresponding difference in mean effectiveness between treatment and control interventions): 
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where CostA and EffectA represent the means of the cost and effect in treatment A and CostB and 
EffectB represent the equivalent in treatment group B (where B is the control intervention). The ICER 
is normally the main summary measure of interest in most economic evaluations, but, as a ratio 
statistic, ICERs can be problematic to work with mathematically (7). The INB transforms comparisons 
of cost and effect instead to a linear scale and is given by: 
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where   is the cost-effectiveness (or willingness-to-pay) threshold is the maximum threshold at 
which a decision-maker is willing to pay per unit of effectiveness gained. INBs can be framed in net 
monetary terms (as given by the equation above) or net health terms which are equivalent (see for 
example Glick et al 2010 (7) for further discussion of cost-effectiveness ratios and INBs). 
In the applications that follow, the INB is used as the statistic for assessing agreement due to the 
mathematical convenience of working on linear scale. If two sources of data are available, Lin’s CCC 
of the two INB estimates will be calculated alongside the difference between the two INB estimates 
with a 95% confidence interval. Compatible with bootstrapping, the commands allow the calculation 
of the PM, the PCE and produce a simple plot assessing the cost effectiveness. 
The current version of the package only allows for assessment of two datasets where the 
comparison involves analysis of individual participant data on costs and effects (binary or continuous 
measures), such as that from a simple two-arm randomised controlled trial data. Future 
development will focus on extending the routines to allow for i) RCTs with more complex designs 
(cluster-randomised, multiple-treatment comparisons, etc.), ii) inclusion of adjustment covariates in 
a regression so routines can be applied to comparisons involving non-randomised study designs and 
iii) allowing greater customisation of the graphical output. 
 
2 THE COMMANDS 
2.1 DESCRIPTION  
The heabs command calculates the ICER and INB for up to two pairs of cost effectiveness data. The 
command is flexible, and if just one pair of cost and effect variables are entered then only the ICER 
and INB will be calculated. However if two sets of cost and effect variables are presented, then the 
command calculates the ICER and INB for both data sources, and performs a simple comparison of 
the INB scores, calculating the CCC and the difference in INB estimates and relative confidence 
interval. In addition to cost/effect data, the function also requires the user to input the willingness-
to-pay threshold and whether or not a higher score in the effect variable is beneficial (e.g. quality of 
life) or detrimental to the health of the individual (e.g. mortality). The command also requires the 
treatment indicator variable to be encoded 0 and 1. heabs stores a range of calculated values, 
allowing for simple use alongside Stata’s built-in bootstrap command.  
Lin introduced his CCC as a means of quantifying agreement between two measures(6). It follows 
traditional correlation coefficients, with a score of 1 suggesting perfect agreement, -1 suggesting 
perfect inverse agreement and 0, no agreement. In 2005, McBride (8) suggested that moderate 
agreement could be identified if the lower 95% confidence interval of the CCC estimate was above 
0.90. However, Cichetti (9) suggests a score as low as 0.4 can be taken as a measure of fair 
agreement. With such a wide range of views, it is recommended the user decide their own suitable 
CCC threshold for determining agreement.  
Similarly, the difference in incremental net benefit has no firm interpretation in terms of its 
assessment of agreement. The standard errors will often be large, reflecting the wide range of costs 
associated with a typical health economic analysis. Hence, it is unlikely that a significant difference 
will be found between the two sources of data. Again, it is recommended the user establish an 
acceptable level of difference between the two sources of data, and examine the results of the 
bootstrap accordingly. 
The heapbs command calculates the PMC and PCE for a set of cost effectiveness data that has 
been generated through the use of heabs command combined with the bootstrap function. It can 
also produce a scatter plot of the cost effectiveness data fitting a confidence ellipse around the data. 
The command is flexible, calculating only the scores specified by the user.  
The PMC is recommended by Achana et al (5) to be implemented by taking the INB from the routine 
data source, and the confidence intervals of the gold-standard trials data. This will then yield the 
probability that the confidence intervals do not contain the INB estimate, allowing for assessment of 
the agreement between the sets of data. 
The PCE, whilst not a direct assessment of agreement, allows the user to assess what percentage of 
their bootstrapped INB estimates for a dataset are positive (i.e. cost effective). A comparison of the 
PCE for both sets of cost effectiveness data could yield further insight into the agreement of the two 
sources. 
Finally, the optionally generated graph allows for the visual interpretation of a set of cost 
effectiveness data through a scatter plot, complete with a 95% confidence ellipse. The ellipse is 
generated using an incorporated version of the command ellip (10). This command calculates the 
confidence ellipse assuming the costs and effects are elliptically distributed, drawing the ellipse with 
twoway line. The fitted ellipse should contain roughly 95% of the scattered points. 
 
2.2 SYNTAX 
 
heabs cost1 effect1 [cost2 effect2], w2p(#) intervention(varname) 
  response(string)  
 
cost1 and effect1 represent the cost and effect variables obtained from the first dataset.  
cost2 and effect2 are the variables from the second dataset, required if a comparison is to be 
performed. If the second pair of variables is not provided, the command. All of these variables must 
be numeric without any missing data.  
w2p is the willingness to pay threshold, used in the calculation of the INB. This reflects how much 
the decision maker is willing to pay per unit of effect.  
intervention is used to specify the variable which indicates which treatment arm individuals are 
in. It requires that 0 and 1 are used to distinguish between the two treatment arms.  
response is used to specify whether a higher score in the effect variables should be interpreted 
positively (e.g. response to treatment) or negatively (e.g. death). The response variables can contain 
either binary (yes/no) data or be continuous measures.  
 
heapbs, [lci(varname) uci(varname) ref(#) inb(varname) draw 
  cost(varname) effect(varname) twoway_options] 
 
lci is used to specify the variable containing the bootstrapped estimates of the lower 95% 
confidence interval of the INB. Needed for PMC calculation. 
uci is used to specify the variable containing the bootstrapped estimates of the upper 95% 
confidence interval of the INB. Needed for PMC calculation. 
ref is the reference INB to be used in the PMC. Achana et al (2017) (5) suggest using the INB from 
one dataset as the reference and comparing with the 95% confidence intervals of the other dataset. 
inb is used to specify the variable containing the bootstrapped estimates of the INB. Needed for 
PCE calculation 
draw option to be used if user would like to generate a plot of the cost effectiveness bootstrapped 
data with a confidence ellipse. 
cost is used to specify the variable containing the bootstrapped cost estimates. Needed to draw 
plot. 
effect is used to specify the variable containing the bootstrapped effect estimates. Needed to 
draw plot. 
twoway_options allow the control of titles, legends, axis and ellipse settings. See the ellip 
command for further details. (10) 
2.3 SAVED RESULTS 
 
heabs saves in r(): 
Scalars 
r(cost1)  Incremental Cost from the first set of cost effectiveness data 
r(outcome1) Incremental Effect from the first set of cost effectiveness data 
r(cost2)  Incremental Cost from the second set of cost effectiveness data 
r(outcome2) Incremental Effect from the second set of cost effectiveness data 
r(NB1)  INB from the first set of data 
r(seNB1)  SE of the INB from the first set of data 
r(loCINB1)  Lower 95% confidence interval of the INB from the first set of data 
r(upCINB1)  Upper 95% confidence interval of the INB from the first set of data 
r(NB2)  INB from the second set of data 
r(seNB2)  SE of the INB from the second set of data 
r(loCINB2)  Lower 95% confidence interval of the INB from the second set of data 
r(upCINB2)  Upper 95% confidence interval of the INB from the second set of data 
r(diffNB)  Difference in the INB estimates of the two sets of data. 
r(ICER1)  ICER from the first set of data 
r(ICER2)  ICER from the second set of data 
r(cccNB)  CCC estimate of the two sources of data 
r(zcccNB)  Z score of CCC estimate, can be used in hypothesis testing 
 
heapbs saves in r(): 
Scalars 
r(pce)   Probability of Cost Effectiveness 
r(pmc)   Probability of Miscoverage 
3 EXAMPLE 
 
A quick example of the commands is shown through manipulation of the bpwide.dta built in dataset, 
which can be reproduced using the do file included in the package. Blood pressure is the outcome of 
interest, with a higher score associated with poorer health. Gender is recoded as the intervention 
indicator, and artificial cost data is created, loosely based on the blood pressure data. The ‘before’ 
variable is treated as the first gold standard trial data set, and the ‘after’ variable treated as the 
comparator. The full list of changes is shown through the commands below. 
sysuse bpwide, clear 
set seed 123 
_strip_labels _all 
drop agegrp 
gen cost1 = (200-bp_before)*rnormal(50,10) 
gen cost2 = (250-bp_after)*rnormal(50,10) 
rename bp_before bp1 
rename bp_after bp2 
rename sex intervention 
 
Once the data set is prepared, the functions can be applied as follows. 
Firstly, with no second source of data indicated, the command performs a simple routine cost 
effectiveness analysis. The output displays a summary of the data followed by estimates of the ICER, 
INB and INB SE. 
. heabs cost1 bp1, int(intervention) resp(detr) w2p(10) 
Summary:            Int 0           Int 1 
       N               60              60 
       Min Cost        98.84935        667.84314 
       Max Cost        3700.2056       3592.1421 
       Min Effect      140             138 
       Max Effect      185             185 
 
--------------------------------------------------------------------------+ 
         | Cost       |  Effect    | Inc Cost   | Inc Effect | ICER       | 
---------+------------+------------+------------+------------+------------| 
  Int 0  |  2049.930  |   159.267  |            |            |            | 
         |            |            |   262.202  |     5.633  |    46.545  | 
  Int 1  |  2312.132  |   153.633  |            |            |            | 
--------------------------------------------------------------------------+ 
 
-----------------------------------------+ 
             | INB         |  INB SE     | 
-------------+-------------+-------------| 
  INB Results|  -205.869   |   118.961   | 
-----------------------------------------+ 
If a second set of data is added, then a comparison is performed additionally to the routine analysis. 
Here the estimates for the first data set are unchanged from above, but the corresponding estimates 
for the second data source are also displayed. In addition, the CCC estimate and the difference of the 
INB estimates are shown. Note that is a willingness-to-pay threshold of £10 per unit decrease in 
blood pressure is used, both sources of data agree that the intervention is not cost effective, yielding 
negative INB scores. The CCC suggests very weak agreement between the two sources of data, and 
we can see the difference in the INB estimates is 110.85 units. However the ICERs are very similar, 
with less than 2 units difference. 
 
. heabs cost1 bp1 cost2 bp2, int(intervention) resp(detr) w2p(10) 
Summary:               Data 1                          Data 2 
                  Int 0           Int 1           Int 0           Int 1 
   N             60              60              60              60 
   Min Cost      98.84935        667.84314       2947.646        2947.646 
   Max Cost      3700.2056       3592.1421       7765.9072       7765.9072 
   Min Effect    140             138             125             127 
   Max Effect    185             185             185             178 
 
-----------------------------------------------------------------------+ 
         | ICER       |  INB       | INB SE     |  CCC    | Diff INB   | 
---------+------------+------------+------------+---------+------------| 
  DATA 1 |    46.545  |  -205.869  |   118.961  |         |            | 
         |            |            |            |  0.075  |  -110.853  | 
  DATA 2 |    48.083  |  -316.722  |   197.863  |         |            | 
-----------------------------------------------------------------------+ 
 
The relationships between the CCC estimate and the INB estimate can be shown by changing the 
willingness-to-pay threshold. Below, the threshold is increased to £100 and whilst the ICERs and INB 
estimates suggest that the treatment is now cost effective, the CCC is negative and the difference 
between the INB estimates has increased. A negative CCC implies that the datasets are closer to 
drawing opposite conclusions than perfect agreement. Whilst this appears strange, given the 
apparent agreement of the INB estimates and ICERs, an investigation of the cost and blood pressure 
scores explains why. In Figures 1 and 2, it can be seen that whilst the data is paired, there is very 
little correlation between the two sources of data for both the costs and blood pressure scores. It 
just so happens that the populations agree. It is reasonable to expect a higher correlation between 
real paired individual level data. 
 
 
-----------------------------------------------------------------------+ 
         | ICER       |  INB       | INB SE     |  CCC    | Diff INB   | 
---------+------------+------------+------------+---------+------------| 
  DATA 1 |    46.545  |   301.131  |   123.958  |         |            | 
         |            |            |            | -0.041  |   130.647  | 
  DATA 2 |    48.083  |   431.778  |   208.976  |         |            | 
-----------------------------------------------------------------------+ 
 
 
 
 
Figures 1 and 2: Scatter plots showing the relationship between the costs and blood pressure scores 
of the sources of data. 
The command can be implemented simply within the bootstrap function of Stata, as demonstrated 
below. The key variables used for the heapbs command are shown, however additional outputs 
can be added. 
. bootstrap  cost1=r(cost1) cost2=r(cost2) effect1=r(outcome1) 
effect2=r(outcome2) NB1=r(NB1) NB2=r(NB2) NB1Lo=r(loCINB1)  
NB1Up=r(upCINB1) NB2Lo=r(loCINB2) NB2Up=r(upCINB2), 
saving(dummybpBS, replace)  reps(100) seed(24): heabs cost1 bp1 
cost2 bp2,  w2p(10) int(intervention) response(detr) 
 
------------------------------------------------------------------------------ 
             |   Observed   Bootstrap                         Normal-based 
             |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       cost1 |   262.2021   136.2642     1.92   0.054    -4.870776    529.2751 
       cost2 |   399.8885     203.18     1.97   0.049     1.663059    798.1139 
     effect1 |   5.633333   1.824368     3.09   0.002     2.057638    9.209029 
     effect2 |   8.316667   2.338167     3.56   0.000     3.733945    12.89939 
         NB1 |  -205.8688   122.2152    -1.68   0.092    -445.4063    33.66862 
         NB2 |  -316.7218   190.0119    -1.67   0.096    -689.1382    55.69465 
       NB1Lo |  -439.0318   120.8765    -3.63   0.000    -675.9454   -202.1182 
       NB1Up |   27.29416   124.7917     0.22   0.827     -217.293    271.8813 
       NB2Lo |  -704.5338   186.0972    -3.79   0.000    -1069.278     -339.79 
       NB2Up |   71.09025   197.8324     0.36   0.719    -316.6542    458.8347 
------------------------------------------------------------------------------ 
 
Once a bootstrapped dataset has been created, stored and loaded into Stata, the heabps command 
can be applied. Here, the second dataset is treated as our routine data set, and the first as the gold 
standard data. The text output from the command shows that the PMC is 21% meaning that the INB 
estimate from the second source of data fails to appear within the 95% confidence interval from the 
bootstrapped dataset for the first source of data 21% of the time. The PCE estimate suggests that for 
the willingness-to-pay threshold selection during the bootstrap run, the drug is only cost effective 
4% of the time. 
. heapbs, lci(NB1Lo) uci(NB1Up) ref(-316.722) inb(NB2) draw  cost(cost2) 
effect(effect2) 
Probability of Miscoverage = 21% 
Probability of Cost Effectiveness = 4% 
 
The graphical output is shown in Figure 3. Here, the scatter plot for the second source of cost 
effectiveness data shows the intervention showing the treatment to be more effective and more 
expensive in the majority of bootstrap runs, with a 95% confidence ellipse and mean values clearly 
indicated.  
 
Figure 3: Plot of cost-effectiveness data for second source of data with 95% confidence ellipse. 
 
4 CONCLUSION 
The heabs and heapbs commands described and demonstrated in this article are simple tools to 
aid with the evaluation of individual level cost effectiveness data. They also give the user the 
opportunity to compare two sources of cost effectiveness data, with the aim of enabling more 
efficient clinical trial designs in the future. The flexibility of the commands allow the user to only 
calculate the values they require, and to customise the graphical output accordingly. 
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